Clinical TrialJul 9, 2026, 08:11 AM
Forte Biosciences FB102 Phase 1b Vitiligo Study Shows Significant Improvement
AI Summary
Forte Biosciences announced positive results from its FB102 double-blind placebo-controlled Phase 1b study in vitiligo. The study showed statistically significant improvement in vitiligo, with FB102 achieving a 29.6% mean FVASI improvement from baseline at week 24. Improvements were observed early, by day 64, and continued through the 24-week period, with a strong safety profile. The company will host a conference call to discuss these findings.
Key Highlights
- FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020).
- Statistically significant improvements observed by day 64 (p=0.023), continuing through week 24.
- FB102 showed 43.2% mean FVASI improvement in subjects with baseline FVASI ≥0.75 (p=0.006).
- FVASI50 achieved in 34.4% of FB102 treated subjects overall, and 58.8% in severe cases.
- 84% of FB102 treated subjects improved from baseline to week 24, with 0% worsening.
- FB102 demonstrated a strong safety profile with only mild to moderate adverse events.
- The company will host a conference call on July 9, 2026, to review the study results.
Price Impact
More from FBRX